ReviewEuropean thyroid journal2026
The caprices of a trace element: selenium's considerable effects on Hashimoto's thyroiditis, though few on Graves' disease.
Review in European thyroid journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Abstract: A simplified figure displaying the main events leading to Hashimoto's thyroiditis and Grave's disease via Th1 and Th2 activation, and the potential sites of selenium (Se) action. (A) Activated by the dendritic cell, naïve helper T cells (CD4+ T cells) can mainly differentiate into two subsets, Th1 and Th2, which are crucial in orchestrating immune responses. Th1 cells produce tumor necrosis factor (TNF-a) along with interferon-γ (IFN-γ), exacerbating inflammation, in synergy with interleukin-6 (ΙL-6), leading to apoptosis (death of follicular cells). In parallel, oxidative stress induces activation of the nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB) pathway by reactive oxygen species (ROS) and the phosphorylation and degradation of NF-κB inhibitors, thereby allowing NF-κΒ to translocate to the nucleus. NF-κB acts in the nucleus as a master transcription factor in the nucleus, significantly increasing IL-6 production in various cell types. Se supplementation decreases IL-6 production, thereby mitigating the inflammatory process: it activates antioxidant enzymes and increases Treg cells, restoring the balance with Th17 cells. Th2, by producing interleukins, promotes B cell differentiation into plasma cells that produce massive amounts of IgG antibodies, which stimulate the TSH receptor on thyrocytes, promoting thyroid hyperplasia and hyperthyroidism. In mild thyroid eye disease (TED), Se abolishes the effects of oxidative stress in interorbital fibroblasts, reducing hyaluronic acid release, decreasing inflammation, and potentially lowering the production of glycosaminoglycans (GAGs). (B) Se enhances selenoprotein P (SELENOP) and glutathione peroxidase (GPX) activity; it is significantly involved in redox processes within the thyrocytes, scavenging H2O2, and its reactive by-products (e.g. hydroxyl radicals) through oxidation-reduction cycles. GPX neutralizes the hydrogen peroxide (H2O2) produced during thyroid hormone synthesis. This process is essential for maintaining a healthy balance (redox homeostasis) within the thyroid gland. The effects are inversely related to basal Se levels.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.